share mil
creat bluematrix
gbola amusa md cfa head hc research
sale trade et
sale trade et
initi buy compet
softwar life
initi coverag buy rate
potenti mrna therapeut platform
establish new disrupt class medicin driven
messeng mrna medicin platform compet lipid
formul manufactur quickli emerg
portfolio half clinic target interest
opportun infecti diseas immuno-oncolog rare diseas
cardiovascular diseas space due central role mrna
biolog process therapeut direct cell
produc intracellular membran secret protein therefor
potenti util across spectrum diseas thu pursu
therapeut system secret therapeut system intracellular
therapeut demonstr preclin clinic proof-of-concept
number indic attract attent big
biopharma on-going valid de-risk collabor
profit-shar merck co unrat astrazeneca unrat
summar compon buy rate us
core long-term hold genet medicin investor
given role mrna softwar life
platform offer potenti disrupt solut import
technolog could theori use express almost protein
bodi therefor use treat diseas thu consid
core long-term hold investor look exposur
genom revolut emerg genet medicin
consist biochem properti lnp-deliv
mrna enabl read-across within modal
success expect learn exampl safeti dose
pharmacokinet read across product candid share
mrna lnp chemistri well administr
rout enabl faster develop follow-on program relat
modal also build prior knowledg prophylact vaccin
increasingli extens human dose increasingli de-risk
safeti platform develop candid
dose healthi volunt prophylact vaccin
program even modal includ
larg favor toxic profil far mitig safeti risk key
concern look new therapeut class
pleas refer import disclosur inform regul analyst certif found page report
earli invest digit infrastructur manufactur enabl program move quickli
evidenc compani abil effici advanc program clinic way
near term flexibl in-hous gmp manufactur capac norwood meet grow clinic demand
public high-profil peer-review journal provid vet scienc
publish extens journal like natur medicin scienc translat medicin view
import extern valid approach
partner larg higher-risk indic mitig certain risk exampl partner certain
oncolog indic reduc cash burn profit share merck unrat astrazeneca
unrat maintain opportun upsid blockbust opportun progress market
price target base probability-adjust model key franchis use dcf wacc
perpetu growth impli termin ebitda multipl deriv price target
risk achiev target price
clinic risk face vari degre clinic risk across differ modal develop pipelin
although lnp-deliv mrna gener well-toler prophylact vaccin clinic toxic could
emerg long-term repeat dose system therapi cancer vaccin intratumor immunotherapi
program target difficult-to-treat cancer clinic trial recapitul robust immun
activ seen preclin set show modest anti-tumor efficaci reveal unexpect advers event
would materially-neg impact project price target
regulatori certainti asset approv reimburs us elsewher
regulatori pathway prove complex and/or time consum anticip could materially-
neg impact project target price even result variou franchis achiev target
endpoint product obtain regulatori approv risk-adjust project price target would
expos downward revis concern includ approv narrower-than-expect indic approv
commerci potenti target indic may larg project possibl due
competit rna-bas vaccin oncolog asset develop privat curevac
privat well vector-bas genet medicin rare diseas develop compani includ logicbio
buy unrat neutral unrat sangamo therapeut
unrat price therapi might prove high market bear addit
build sale market medic affair infrastructur us possibl global region
intellectu properti establish intellectu properti estat includ patent mrna engin
lnp compon deliveri manufactur process well around specif develop candid certain
patent expiri date rang possibl patent challeng
manufactur face manufactur risk particular regard person cancer vaccin program
product custom-mad patient individu manufactur therefor complex process
involv collect patient tumor blood sampl sequenc analysi identifi mutat manufactur
custom mrna complex process increas risk manufactur failur variabl
financ risk like need rais addit capit fund preclin develop clinic trial
perhap via equiti financ reach profit potenti result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
clinical-stag biotechnolog compani develop therapeut vaccin base messeng rna
mrna applic infecti diseas immuno-oncolog rare diseas cardiovascular diseas
mrna medicin design direct cell produc intracellular membran secret protein therefor
potenti util across spectrum diseas strateg allianc astrazeneca merck co
page
defens advanc research project agenc darpa biomed advanc research develop
author barda found headquart cambridg massachusett
page
summari lead platform develop mrna-bas therapeut
risk thesi
human metapneumoviru hmpv human parainfluenza vaccin market forecast
cancer vaccin activ patient immun system attack cancer
differ cancer vaccin modal use augment anti-tumor respons
person cancer vaccin multipl solid tumor
current develop phase clinic trial
definit cell respons seen dose higher dose treatment on-going
kra frequent mutat mani solid tumor
approach kra vaccin target common mutant variant
background intratumor oncolog asset multipl cancer
pathway key co-stimulatori pathway cell regul
preclin data suggest deliveri trigger tumor clearanc set
current phase trial relapsed/refractori tumor
background mrna triplet design turn cold tumor hot
page
combin immunostimulatori protein strong preclin efficaci
background intratumor deliveri stimul immun function
strong immun activ system treatment hamper toxic
preclin data show synergi therapi
background vaccin cytomegaloviru cmv infect
target congenit cytomegaloviru infect reduce/prev birth defect
lnp-formul vaccin mrna encod cmv antigen
preclin studi show induct neutral antibodi pentam gb
background vaccin candid chikungunya viru
use viral-lik particl vlp elicit immun respons chikungunya
vlp assembl mrna encod structur protein immunogen
background vaccin influenza
moderna mrna vaccin potenti swiftli address pandem situat
background vaccin zika viru
focus show insuffici immunogen
background respiratori syncyti viru rsv
merck unrat initi phase iia studi base phase trial result
background metapneumoviru mpv parainfluenza viru
potenti address pathogen caus respiratori tract infect
background ischem heart failur
produc vascular endotheli growth factor vegf-a stimul angiogenesi
system secret therapeut target chikungunya viru heart diseas fabri diseas
system intracellular therapeut target mma pa pku
sale key product
page
summari lead platform develop mrna-bas therapeut
initi coverag inc buy leverag scientif expertis build lead
platform advanc messeng rna mrna -base therapeut
messeng rna mrna -base therapeut potenti address broad array mrna natur
produc transcript dna carri genet information/messag encod within dna
decod cellular machineri process call translat lead product protein due number
advanc includ understand molecular mechan translat synthet mrna deliv
vitro vivo produc desir protein mrna therapeut sever advantag includ need
enter cellular cytoplasm function mrna pose risk mutagenesi integr
genom short-liv transient activ degrad via natur pathway rel
inexpens produc reason mrna advanc multipl diseas area includ infecti
diseas cancer vaccin well protein replac therapi oncolog cardiolog endocrinolog
hematolog pulmonari medicin thu support potenti mrna-bas therapi address divers diseas
deliv mrna regul decod host cell machineri correspond bioactiv protein synthet
mrna intend use therapeut design structur element featur mimic naturally-
occur mrna molecul take advantag cellular translat machineri produc protein product
process translat mrna protein occur cytoplasm compart cell cellular
membran restrict coupl presenc rna degrad enzym rnase effort taken ensur
stabil effici deliveri mrna cytoplasm insid cytoplasm therapeut also subject
complex regulatori mechan appli naturally-occur mrna vivo half-lif synthet mrna
manipul variou chemic modif rna molecul well use differ deliveri
invest resourc strengthen technolog platform includ improv deliveri
manufactur compani invest signific resourc research understand mrna therapeut
includ effort limit undesir immunogen mrna increas potenc molecul
chemic modif mrna build block also invest research improv deliveri
technolog protect mrna degrad ensur get cytoplasm translat end
compani improv lipid nanoparticl deliveri strategi enabl safe effici deliveri mrna cargo
moderna sq ft manufactur facil capac produc cgmp lot per compani
complet construct sq ft manufactur facil locat norwood facil meet current
manufactur practic cgmp specif capabl suppli materi manufactur fill/finish
sahin et al mrna-bas therapeut -- develop new class drug drug disc
svitkin yv et al mrna enhanc translat independ mechan
sabni et al novel amino lipid seri mrna deliveri improv endosom escap sustain pharmacolog safeti
sergeeva ov et al mrna-bas advanc perspect biochemistri mosc
kaczmarek jc et al advanc deliveri rna therapeut concept clinic realiti genom
page
compani preclin phase phase ii studi intern manufactur enabl compani manag
qualiti suppli materi also give flexibl would sole reli
contract manufactur organ norwood facil compani indic initi produc
cgmp mrna lot per year expand produc cgmp lot per year could enabl
expand pipelin certain scenario produc commerci suppli need note cgmp mrna lot
quantiti mrna need run singl phase clinic trial
compani pipelin program clinic broadli divid modal figur modal
approach enabl quickli advanc develop candid dc clinic program
program pipelin current program clinic trial pipelin program
divid broad modal describ
prophylact vaccin prevent control infecti diseas design educ immun
system pre-exposur antigen pathogen virus compani collabor merck
co unrat commerci vaccin well defens advanc research project agenc darpa
biomed advanc research develop author barda global health vaccin program
prophylact vaccin modal includ pre-phas ii respiratori syncyti viru collabor
merck phase cytomegaloviru phase
combo vaccin human metapneumoviru hmpv parainfluenza viru preclin
varicella zoster viru collabor merck phase influenza type
phase influenza type preclin zika viru mrna-
phase chikungunya viru
cancer vaccin design trigger enhanc immun system respons antigen creat
mutat protein specif patient tumor neoantigen order promot tumor clearanc pipelin
program modal compani collabor merck includ phase
person cancer vaccin pcv preclin vaccin target
common mutat kra oncogen current open ind program evalu
vaccin monotherapi well combin merck pembrolizumab keytruda
intratumor immuno-oncolog product design deliv immunostimulatori agent tumor
microenviron tme enhanc anti-tumor immun respons program modal includ
phase phase
preclin ind activ
local regen therapeut design regener diseas injur tissu local
product protein provid therapeut benefit target tissu program phase iia
advanc compani collabor astrazeneca unrat
system secret therapeut design increas level desir protein antibodi
enzym replac therapi across multipl diseas area includ heart failur infecti diseas rare
genet disord program modal includ phase collabor
darpa antibodi chikungunya viru preclin collabor astrazeneca secret relaxin
protein heart failur preclin fabri diseas
page
system intracellular therapeut design increas level intracellular protein enzym
mutat rare genet diseas program modal includ preclin ind open
methylmalon acidemia mma preclin propion acidemia pa preclin
phenylketonuria pku
adapt corpor document chardan
figur moderna pipelin program clinic divid modal
multi-sector collabor includ larg cap pharma valid platform compani struck
multipl allianc serv de-risk platform includ collabor larg biopharmaceut compani
astrazeneca unrat merck co unrat unrat also allianc
government-sponsor privat agenc involv global health defens advanc research project
agenc darpa biomed advanc research develop author barda melinda gate
cancer vaccin shown limit efficaci past platform approach posit succeed
cancer vaccin around sinc hundr phase ii trial carri therapeut
vaccin sipileucel-t approv earli vaccin studi differ current studi number key
factor earli cancer vaccin hamper limit understand tumor microenviron immuno-
surveil mechan lack biomark predict patient would like respond factor better
understood today ici era earli vaccin typic limit antigen person enabl escap
heterogen tumor popul unlik candid mani vaccin neo-antigen
finn oj dawn vaccin cancer prevent immunol doi
page
protein highli express tumor normal tissu lead potenti loss reactiv immun cell
mechan evolv maintain toler self tissu due limit understand timelin
associ immune-medi tumor clearanc earli cancer vaccin trial optim design detect
durabl cancer vaccin respons multi-neoantigen approach partnership merck leader
cancer immunotherapi space increas chanc success
infrastructur includ digit integr increas effici qualiti maintain data integr
invest robot cloud-bas program enabl plug-and-play approach design mrna
user input raw paramet get fulli optim end product platform ensur process mrna
therapeut develop effici high qualiti compani use proprietari web-bas system scientist
request mrna interest optim compani proprietari bioinformat system digit
order coupl compani high throughput system increas speed effici therapeut
develop serv maintain data integr compani
risk thesi
mrna use vivo may elicit innat immun respons reduc efficaci mrna although mrna
therapeut sever advantag dna-bas therapeut mrna capac elicit innat immun
respons may limit applic mrna-bas therapeut vivo set attempt address
nucleotid modif prevent interact mrna therapeut innat immun respons
element natur distinguish exogenously- endogenously-deriv rna molecul
deliveri mrna therapeut remain challeng could risk associ system deliveri like
nucleic acid mrna deliveri cell challeng mani reason includ fact cellular membran
natur select even though develop lipid nanoparticl lnp -base approach deliv mrna
therapeut challeng still exist due mani factor includ mrna instabl lead reduc half-lif system
deliveri requir higher dose need case requir repeat dose
mrna unstabl subject rna nucleas lead short half-lif vivo reduc efficaci mrna
subject degrad nucleas ubiquit cytoplasm mrna would need translat
protein potenti lead reduc efficaci employ strategi lead increas half-
life mrna therapeut nucleas pose challeng especi indic requir sustain protein express
product high level protein
mrna-bas therapi approv regulatori preced even though mrna-bas
therapeut advanc clinic variou indic current approv mrna therapi
absenc approv therapi like regulatori framework mrna-specif therapi
make advanc everi step therapeut develop convinc regulatori author
face competit compani drug candid diseas area competit select
mcivor sr therapeut deliveri mrna medium messag mol ther
page
chikungunya face competit valneva unrat live-attenu vaccin
candid fda track design ftd develop phase report
posit result themi bioscienc privat also advanc live-attenu vaccin mv-chik phase ii
compani recent publish phase ii studi result plan initi phase
zika viru valneva collabor emerg biosolut buy analyst keay naka vaccin
candid phase report posit result nih conduct phase ii
studi dna-bas vaccin expect complet
oncolog compani unrat unrat privat
among other develop person neoantigen cancer vaccin vaccin share tumor antigen
develop compani well other
varieti therapeut agent modul tme develop across multipl modal includ
agonist antibodi unrat genentech unrat viral plasmid-bas immunotherapi
deliv immunostimulatori protein develop replimun unrat ziopharm unrat
oncoru privat oncosec unrat among other
mma face competit logicbio buy use vivo gene edit
technolog approach selecta bioscienc unrat use aav-bas gene therapi approach
page
figur broad pipelin gener abund newsflow
page
dateeventchardan mrna pcd pi chikungunya vax trial hvplacebo-control dose-rang studi test antigen mrna pcd pi influenza vax trial outcom solicit unsolicit day cambridg annual competit data neon tx pcv solid peptide-bas cancer vaccin test combo mrna pcd pi trial healthi adultsinterim data show nab titer baselin hmpv day new york citi annual pcv neoantigen mrna pcd pi trial solid monotx resect tumor combo pembro competit pcd biontech pi merit trial pcv arm trial test rna-bas pcv patient cancer competit logicbio submit ind employ nuclease-fre genom edit deliv function mut competit biomarin submit ind bmn pkubmn gt deliv function pah competit prelim data oncosec tavo trial tnbcol trial evalu tavo plasmid electropor hvegf-a mrna data patient undergo cabg surgeryperfus cardiac function data random mrna astrazeneca start pi trial solid tumorsu profit share astrazeneca royalti ex-u cmv vaccin pi safeti immunogen data startplacebo-control dose-rang studi test mrna pi data meet pib studi startinterim data show nab titer baselin hmpv rsv-f mrna merck start trial rsv vaccinemerck pay mileston anti-chikungunya igg mrna pi data chikungunyasafeti serum ab level outcom pk/pd mab mrna initi dose adv ovarian cancer cohortintratumor admin object determin immun respons mrna finish d-e pi r/r solid intratumor admin arm mono tx combo iv hmut mrna pi start safeti poc biomark data mmathi trial import comp mrna vs genet pcv neoantigen mrna pi clinic activ datarandom trial start pi data kra neoa mrna merck start pi trial pi t-cell immunogenicityglob profit share file zika fabri diseas relaxin pa pkuw expect show increas tangibl valu next competit data homolog pi/ii trial adult pkuhomolog plan begin trial aavhsc-bas gt deliv pah mrna pcd pi/ii trial r/r solid tumor lymphoid caintratumor admin object determin immun respons cmv vaccin pcd pi cmv vax trial healthi adultsplacebo-control dose-rang studi test hvegf-a mrna pcd studi pt undergo cabg surgeryintracardiac inject vs placebo endpt blood flow mrna pcd pi r/r solid intratumor admin arm mono tx combo iv anti-chikungunya igg mrna pcd pi trial healthi mrna-encod mab outcom pk/pd mab competit data neon tx pcv evalu combo pembrolizumab pcd nh trial pt mma paevalu chang plasma biomark frequenc clinic event pcv neoantigen mrna pcd trial combo pembro vs pembro alon outcom hmut mrna pcd pi/ii dose escal trial mmapati age year outcom te chang plasma expiri leas sq ft norwood manufactur facil option extend leas expect expiri company-own platform patentsthes includ platform patent mrna chemistri deliveri expect expiri patent rna vaccin programsthes includ patent famili cmv mpv expect expiri patent system intracellular therapeut programsthes includ patent famili mma pa pku line cabg coronari arteri bypass graft cmv cytomegaloviru hmpv human metapneumoviru hv health volunt ici immun checkpoint inhibitor mma methylmalon acidemia maximum toler dose nab neutral antibodi nh natur histori neoa neoantigen nsclc non-smal cell lung cancer ol open label pa propion acidemia pah phenylalanin hydroxylas pcd primari complet date endpoint pcv person cancer vaccin parainfluenza viru pku phenylketonuria teae treatment-emerg advers event tnbc tripl neg breast cancer inc
figur broad pipelin reflect applic vast opportun mrna-bas therapeut
page
modalityproduct candidatemileston chardan estim ww rightsstag developmentpreclinphas common kra mutat neoantigen mrna im nsclc pancreat cancer merck start phase trial phase t-cell immunogen fusion protein mrna im metapneumoviru hmpv parainfluenza viru pcd phase trial healthi adult pi safeti immunogen data medic meet pentamer gh gl plu gb mrna im cytomegaloviru pi safeti immunogen data start pcd phase trial healthi subjectscancervaccinesintratumoralimmuno-oncologyprophylact structur polyprotein mrna im chikungunya viru pcd phase trial healthi patient cancer vaccin pcv neoantigen mrna im solid hemagglutinin protein mrna im influenza pcd phase trial healthi adult pcd phase trial phase clinic activ data pcd phase ii trial melanomaglob profit share profit share mrna tu solid tumors/lymphoma initi dose phase ii advanc ovarian cancer cohort pcd phase i/ii trial advanc malign barda antigen mrna im varicella zoster viru vzv membrane-anchor pre-fus rsv-f protein mrna im respiratori syncyti viru rsv merck start trialmerck pay mileston viru prm-e structur protein mrna im zika viru ind file merck pay mileston hemagglutinin protein mrna im influenza inc
figur broad pipelin reflect wide applic vast opportun mrna-bas therapeut
page
modalityproduct candidatemileston chardan estim ww right phase data pcd phase trial healthi adult relaxin extend half-lif mrna iv heart failur ind filingu profit share astrazeneca royalti ex-u anti-chikungunya protein igg mrna iv chikungunya viru propionyl-coa carboxylas hpcca hpccb mrna iv propion acidemia pa ind file pcd nh studi mma alpha galactosidas h-gal optim mrna iv fabri diseas ind file methylmalonyl-coenzym mutas hmut engin mrna iv methylmalon acidemia mma phase start phase safeti poc biomark data pcd nh studi mma pa pcd phase i/ii trial stage developmentpreclinphas mrna tu solid tumors/lymphoma initi dose phase ii advanc ovarian cancer cohort pcd phase i/ii trial advanc malign mrna tu solid tumors/lymphomaastrazeneca pay mileston vascular endotheli growth factor hvegf-a mrna id myocardi ischemia finish dose escal phase trial r/r solid cancer/lymphoma pcd phase trial advanc malign mrna tu solid tumor astrazeneca start phase trial solid tumorsu profit share astrazeneca royalti ex-u sale phase iia data patient undergo cabg surgeri pcd phase ii studi patient undergo phenylalanin hydroxylas hpah optim mrna iv phenylketonuria pku ind file inc
figur cytomegaloviru market sale forecast million
page
million follow-on non-risk-adjust sale sale yoy state cmv modelxu popul age birth tri tri tri conceiv first parent cohort receiv cmv vaccin cohort receiv cmv vaccin dose dose cmv vaccin cmv vaccin market product share follow-on share cmv popul birth cohort treat cmv vaccin treat follow on treat cmv per dose cmv sale cmv vaccin yoy sale follow-on sale cmv vaccin inc
human metapneumoviru hmpv human parainfluenza vaccin market forecast
figur market sale forecast million
page
million follow-on non-risk-adjust sale sale yoy state modelxu popul age birth cohort receiv vaccin cohort receiv vaccin dose dose popul cohort receiv influenza vaccin cdc receiv pneumococc vaccin cdcpopul age receiv vaccin age receiv vaccin dose dose dose vaccin deliv vaccin market product share follow-on share popul birth cohort age cohort treat vaccin treat follow on treat per dose sale vaccin yoy sale follow-on sale vaccin inc
figur iio market sale forecast million
page
million non-risk-adjust sale sale yoy azn non-risk-adjust sale sale yoy share us us sale share royalti rate ex-u ex-u royalti state iio modelxu popul age cancer tripl neg cancer receiv receiv azn treat treat azn per patient sale yoy sale azn yoy moderna inc
figur kra market sale forecast million
page
million non-risk-adjust sale sale yoy share global global sale share state kra modelxu popul age metastat metastat metastat receiv treat per patient sale yoy inc
figur cabg market sale forecast million
page
million azn non-risk-adjust sale sale yoy royalti royalti state cabg modelxu popul age receiv mrna procedur mrna mrna therapi market product share azn share mrna procedur mrna treat azn treat mrna per sale mrna therapi use cabg procedur yoy sale sale mrna therapi inc
figur pcv market sale forecast million
page
million non-risk-adjust sale sale yoy share global global sale share state pcv modelxu popul age metastat elig metastat elig metastat elig metastat elig msi-h metastat elig receiv treat per patient sale yoy inc
figur rsv market sale forecast million
page
million non-risk-adjust sale sale yoy royalti royalti state rsv modelxu popul age birth cohort receiv rsv vaccin cohort receiv rsv vaccin dose dose rsv popul cohort receiv influenza vaccin cdc receiv pneumococc vaccin cdcpopul age receiv rsv vaccin age receiv rsv vaccin dose dose rsv dose rsv vaccin deliv rsv vaccin market product share share rsv popul birth cohort age cohort treat rsv vaccin treat follow on treat rsv per dose rsv sale rsv vaccin yoy sale sale rsv vaccin inc
accord cancer gov least cancer death solid tumor
checkpoint inhibitor target shown impress efficaci patient
certain tumor type melanoma patient respond initi respond eventu becom
resist due activ immunosuppress signal pathway
inde patient actual respond ici monotherapi
case challeng due immuno-suppress tumor microenviron limit antigen
present cell subsequ activ
cancer vaccin aim address issu deliv tumor associ antigen order increas chanc
cell prime activ
ampl rational combin vaccin immun checkpoint inhibitor
vaccin stimul expans exist neo-antigen-specif cell popul trigger new cell
respons tumor-specif neoantigen
ici support activ expand cell block signal trigger exhaust
cancer vaccin activ patient immun system attack cancer
adapt cheung mooney dj nano today aug chardan
figur cancer vaccin part broad immunotherapi arsen stimul anti-canc respons
cancer vaccin increas antigen present cell
page
tumor associ antigen taa often releas die cancer cell taken antigen-pres cell
dendrit cell dc turn present cell major histocompat mhc complex
recognit taa conjunct co-stimulatori signal provid dc transmembran protein
activ signal pathway insid cell caus travel toward infiltr
tumor recogn kill tumor cell bear antigen
tumor cell kill cell releas antigen lead epitop spread expans immun respons
cancer vaccin increas likelihood cell exposur taa deliv taa quantiti antigen
cancer vaccin part broader immuno-oncolog approach aim increas anti-tumor immun respons
cancer vaccin sensit immun system tumor creat new cell respons promot expans
exist tumor-specif cell lead divers anti-tumor respons
expand pool tumor-specif cell boost efficaci ici i/o agent
page
differ cancer vaccin modal use augment anti-tumor respons
adapt chardan
figur tumor antigen deliv antigen present cell ex vivo top vivo bottom multipl modal
antigen present cell apc dendrit cell dc load antigen cultur
antigen deliv peptid encod mrna
antigen-load dendrit cell transfer patient often combin adjuv
tumor antigen vaccin also deliv vivo directli peptid encod viral vector dna rna
epitop use cancer vaccin tumor-associ tumor specif
tumor associ antigen highli express cancer cell rel normal cell
tumor-specif antigen neoantigen encod gene mutat cancer absent normal cell
target neoantigen limit likelihood side-effect associ immun attack normal cell
epitop specif patient tumor toward share mutat recur mani patient
page
adapt guo et al front immunol jul chardan
figur person cancer vaccin tailor mutat profil patient tumor
person cancer vaccin pcv strategi predict mutat creat immunogen epitop
dna sequenc patient tumor sampl identifi mutat bioinformat algorithm predict
result mutat neo-epitop peptid aim predict peptid would actual present
mhc hla complex would like activ cell respons
pcv design workflow incorpor protein analysi tumor peptid mass-spectrometri identifi
pcv deliv vivo taken express apc present cell lymph node
antigen-load apc traffic drain lymph node present peptid cell
mhc class class ii complex respect
page
neoantigen vaccin limit class mhc activ cytotox cell other includ
class ii epitop well promot respons
adapt yadav et al natur chardan
figur mice immun peptid deriv neoantigen show slow tumor growth detect cell respons
neo-epitop mous colon cancer line identifi use combin bioinformat strategi
scientist roch unrat subsidiari genentech identifi possibl neo-epitop combin exom
transcriptom sequenc narrow mass spectrometri
mice immun peptid repres neo-epitop combin adjuv show slow
tumor growth compar mice receiv adjuv alon
expans cell specif neo-epitop use vaccin could detect blood higher
individu mice respond vaccin
adapt chardan
figur mice show neoantigen-specif cell respons intramuscular inject lnp-encapsul mrna encod multipl antigen
intern preclin data show cell respons mice inject mrna neoantigen vaccin
page
experi compar cell respons previous publish neoantigen mous
cancer cell line saw robust respons mrna-bas vaccin compar vaccin
consist peptid adjuv mice vaccin day cell analysi take place
day experi
importantli respons specif mutat neoantigen non-mut wild-typ protein
critic safeti paramet regard potenti induct autoimmun
separ experi compani show respons multipl neoantigen encod singl mrna
right
page
person cancer vaccin multipl solid tumor
adapt moderna corpor present chardan
figur person cancer vaccin target neoantigen identifi next-gener sequenc
tailor patient tumor produc batch per patient
tumor biopsi normal tissu dna rna sequenc use identifi human leukocyt antigen hla type
proprietari vaccin design algorithm predict like immunogen neoantigen hla type
design singl mrna encod concatam neoantigen predict trigger
cell respons
neoantigen translat singl protein chain process separ peptid proteasom
vaccin product formul proprietari lnp deliv via intramuscular inject
bioinformat use design pcv integr autom cgmp pcv manufactur process
incorpor single-us system robot facilit scale parallel manufactur single-pati
informat manufactur infrastructur enabl manufactur time order week
gener posit mrna vaccin rel easi manufactur co-express multipl
neoepitop singl mrna
phase clinic suppli manufactur extern network transfer manufactur
capabl new norwood facil capabl manufactur product remaind
phase phase ii trial
note potenti drawback rna vaccin tumor environ promot defect antigen process
present peptid translat insid cell may sub-optim wherea peptide-bas vaccin may
issu
part collabor nation cancer institut moderna pcv also evalu
pcv approach amen tumor type high tumor mutat burden tmb number
mutat tumor lung cancer melanoma would provid broad pool potenti
neoantigen select optim vaccin target pardi et al mrna vaccin new era
page
current develop phase clinic trial
adapt moderna corpor present clinicaltri gov chardan
figur collabor merck complet phase dose-escal expans trial solid tumor
phase studi multipl solid tumor on-going
dose-escal studi part adjuv combin therapi set evalu dose level
part patient receiv adjuv set surgic resect disease-fre
time start trial
primari outcom measur part includ dose limit toxic first week inject
percent subject experienc advers event within day last treatment dose dlt
observ date
part target patient unresect cancer receiv togeth intraven
therapi pembrolizumab given day keytruda cycl cycl
primari outcom measur part focu percent subject experienc advers event within day
last pembrolizumab dose
februari interim safeti data shown dose-limit toxic dlt across patient
trial current enrol expans cohort dose level
secondari outcom measur center biomark respons earli sign anti-tumor activ
part trial evalu biomark level tumor compar baselin day
part also aim analyz antigen specif cell respons peripher blood baselin day post
part addit secondari outcom relaps free surviv rf time-fram year post mrna-
part sever addit secondari outcom measur includ overal respons rate durat respons
progress free surviv overal surviv percent chang blood biomark among other
page
toxic post subject advers event post last doseprimari subject advers event post last pembrodosenon-smal cell lung cancer small cell lung cancer melanoma bladder cancer hpv-neghead neck squamou cell carcinoma msi-high tumor includ colorect stomach esophag endometri cancer monotherapycombin moderna inc
phase ii protocol file fda pcv keytruda resect melanoma high risk recurr
trial design assess whether addit keytruda improv recurrence-fre surviv
patient random combin vs keytruda monotherapi primari endpoint
recurrence-fre surviv month
phase ii trial post-op adjuv set melanoma primari endpoint recurrence-
free surviv month
begin phase studi neoantigen vaccin deliv epitop phase ii trial
vaccin encod neoepitop
definit cell respons seen dose higher dose treatment on-going
adapt chardan
figur antigen-specif cell respons seen patient mg level treatment cycl
detect antigen-specif cell respons patient mg level part
octob immunogen data avail patient part part
measur antigen-specif cell respons isol cell patient peripher blood
stimul cultur peptid correspond encod patient cancer vaccin
use secret interferon gamma readout activ
melanoma patient mg cohort part show cell respons peptid pool cycl
patient dose level show sign respons also dose howev paramet
assay lower limit quantif signific patient result uncertain
compani saw sign immunogen remain patient mg cohort
patient mg cohort
page
anticip higher likelihood posit signal higher dose cohort combin keytruda
preclin mous data figur show dose-depend increas cell respons use similar assay
shown
note mous studi use rel higher dose mous weigh averag
compar mg human approxim weight kg
yet visibl level cell respons seen mous human studi may
reflect tumor regress
kra frequent mutat mani solid tumor
adapt cbioport msk-impact data zheng et al onco target therapi volum page chardan
figur kra frequent mutat mani cancer type
kra gene recurr mutat across mani differ solid tumor includ pancreat lung colon
kra protein central signal pathway involv cell divis surviv respons growth cue
mutat found cancer result singl amino acid chang lead constantli activ kra
protein turn promot uncontrol growth tumor cell
mutat randomli distribut throughout gene tend occur amino acid
page
small number frequent mutat account vast major mutant kra cancer pie chart
show distribut non-smal cell lung cancer
despit extens effort kra signal pathway control proven difficult target
kra protein intracellular protein amen small molecul antibody-bas
redund pathway control kra result rapid evolut treatment resist tumor lead
relaps treatment target therapi inhibit compon kra pathway trametinib
approach kra vaccin target common mutant variant
adapt chardan
figur co-deliv vaccin mutant kra togeth mrna encod activ innat immun system
target common kra mutat cancer aim kill cell rather block signal
unlik target therapi aim inhibit signal pathway downstream kra lead cell death
approach aim activ immun system kill cell mutant form kra protein
minim potenti side effect reduc opportun evolv resist
common mutat account kra mutat cancer
like pcv cancer vaccin encod epitop concatam singl mrna
share neoantigen approach amen patient whose tumor high tumor mutat
burden desir pcv strategi
origin ind submiss neoantigen mrna co-encapsul proprietari lnp togeth
mrna encod constitut activ sting stimul interferon gene
sting activ immun system via interferon signal would expect strengthen immun
respons weaker antigen
page
number small molecul sting agonist develop includ merck
thu far shown littl efficaci monotherapi could part combin regimen
 checkpoint inhibitor
also develop partnership merck sponsor plan phase trial
transfer ind program merck elect first run phase trial use
kra neoantigen alon per moderna sting mrna may requir addit glp tox studi
merck may incorpor sting mrna subsequ trial
merck plan administ togeth checkpoint inhibitor keytruda
maxim immun stimul
ind program current open
preclin data transgen mous model show robust cell respons kra mutat
test respons differ kra variant use transgen mous model express human hla
mice administ mrna togeth mrna encod sting day day show
measur cell respons day stimul differ kra peptid though note
differ respons magnitud peptid also visibl respons
would look like vaccin without sting agonist use phase trial
page
background intratumor oncolog asset multipl cancer
pathway key co-stimulatori pathway cell regul
adapt astrazeneca chardan
figur stimul presenc tumor antigen lead anti-tumor cell activ tumor kill
membrane-bound protein provid co-stimulatori signal promot cell surviv function
transient express cell within hour antigen
ligand bind normal express surfac antigen present cell
bind ligand agonist antibodi promot cell surviv neg
addit promot cell surviv stimul enhanc cytokin secret cell cytolyt activ
cell promot establish long-term memori cell shown deplet
immunosuppress regulatori cell mice
signal axi popular target i/o
sever compani develop agonist antibody-bas approach stimul trial on-going
phase studi mous antibodi show sign anti-tumor efficaci meet
respons criteria like due develop anti-mous immun
phase trial astrazeneca unrat subsidiari medimmun unrat
genentech unrat also on-going advanc solid tumor
popov jaffe em zaidi emerg strategi combin checkpoint modul cancer immunotherapi clin invest
page
agent deliv intraven trial incorpor combin treatment ici rais
potenti system autoimmune-rel toxic
deliveri local tumor lesion immun activ tumor system
lead potenti abscop respons regress lesion elsewher bodi
preclin data suggest deliveri trigger tumor clearanc set
adapt chardan
figur intratumor mrna deliveri rescu surviv mice liver cancer
intratumor inject mrna led improv surviv preclin mous model liver cancer
preclin data packag includ studi syngen mous model hepatocellular carcinoma
cancer cell line transplant subcutan host mous genet
background set function mous immun system
experi mice per condit treat weekli intratumor inject mous mrna
control mrna given day post cancer cell implant
mice given control mrna die sacrif due predetermin excess tumor burden
threshold day mice treat surviv day
surviv mice analyz day detect tumor burden indic complet respons
importantli surviv mice show sign immunolog memori challeng re-inject
cancer cell line mice develop tumor
howev highlight januari public scienc translat medicin mous
tumor line colon carcinoma variant show limit respons could enhanc
set combin treatment discuss
featur design reduc toxic
although initi develop legaci lnp formul switch proprietari lnp technolog
toxic signal pre-ind glp tox
mrna incorpor microrna bind site lower level express hepatocyt therebi
reduc potenti sourc toxic despit intratumor inject
page
experiment system mous syngen hepatocellular carcinoma model implant subcutan balb/c micedeliveri proprietari lnp reduc toxicityadministr weekli intratumoralinject inc
note intratumor i/o asset may combin checkpoint inhibitor boost efficaci
current phase trial relapsed/refractori tumor
adapt moderna corpor present clinicaltri gov chardan
figur moderna phase studi includ dose escal dose expans period detect treatment
phase dose escal trial dose patient januari
open-label trial multicent studi evalu encapsul lipid nanoparticl deliv
via intratumor inject relapsed/refractori solid tumor lymphoma
dose schedul administ day cycl cycl
studi design includ dose cohort shown dose period dose escal period
subsequ expans period recommend dose
octob patient ovarian cancer shown sign tumor regress meet
criteria consid partial respons pr
patient mg mg dose cohort regress seen mg patient occur
dose
per compani treat pair biopsi lesion shown higher protein level
treatment vs baselin shown right cycl day post treatment
protocol amend initi phase ii cohort ovarian cancer dose file
unlik cancer vaccin trial safeti signal emerg program dlt
studi patient experi rapid-onset injection-rel reaction multipl grade grade
revers antihistamin corticosteroid supplement oxygen
suspect unexpect seriou advers reaction susar report grade reaction grade
non-infecti system inflammatori syndrom case skin ulcer treatment deem non-
note patient skin ulcer ultim hospit due worsen ulcer
time inject tumor note absent though lesion present patient die due
diseas progress releas hospit
page
toxic post subject advers event post last doseprimari outcom inc
background mrna triplet design turn cold tumor hot
combin immunostimulatori protein strong preclin efficaci
adapt adapt chardan
figur cocktail immunostimulatori agent
deliv compon stimul immun system tumor
describ serv cell co-stimul activ adapt immun respons bind
receptor cell set antigen recognit stimul expans
gamma pro-inflammatori cytokin famili involv initi inflammatori
note elev gamma observ autoimmun diseas lupu psoriasi could point
potenti toxic system exposur remind mrna intratumor i/o modal
includ microrna bind site limit hepatocyt express order reduc issu system toxic
member famili act link innat immun signal adapt immun activ
like gamma high express associ autoimmun diseas role cancer
complex serv promot cancer progress
see differenti asset current extens pursu i/o space
ngiow sf teng mwl smyth mj balanc cancer trend immunol doi
page
 complet respond complet respond complet respond bilater tumor engraftmentmrna inject right flank inc
preclin data show complet respons rate syngen mous model use mous mrna homolog
shown treatment mice implant bilater cancer cell line mrna
compon result high degre tumor control
note complet respons inject suggest abscop effect effect distant
tumor recapitul human could indic potenti metastat tumor
shown perform similar studi variant cell line resist checkpoint
inhibitor saw similar complet respons rate
januari scienc translat medicin public show superior tumor control via
intratumor deliveri vs subcutan intraderm character immun microenviron chang
associ respons
importantli combin triplet mrna produc cr rate
refractori line demonstr cr rate triplet alon given similar cytokin
respons seen human tumor cell line see rational synergi variou ici
page
adapt adapt chardan
figur phase open-label multicent studi plan evalu solid tumor lymphoma
begun dose patient phase trial unit state israel
trial expect evalu alon combin checkpoint inhibitor
trial design includ studi arm monotherapi combin durvalumab inhibitor pd-
combin tremelimumab inhibitor
studi aim determin safety/toler set well defin
maximum toler dose dose expans portion trial
addit object trial includ metric anti-tumor activ express encod protein within
tumor exploratori endpoint assess immunolog respons
page
stagger armadministr arm everi week dosesarm everi week cyclesarm everi week cycl inc
dose escal arm trial run semi-sequenti arm start dose level arm
clear safeti arm start level arm clear safeti
note world-wide right
background intratumor deliveri stimul immun function
strong immun activ system treatment hamper toxic
adapt berraondo et al clin cancer chardan
figur cytokin central regul anti-tumor immun
signal stimul anti-tumor activ across innat nk cell adapt cell immun system
signal promot secret anti-tumor cytokin interferon gamma turn promot varieti
interferon gamma signal also mediat sever sometim lethal toxic seen deliveri includ
sever hematolog toxic transamin inflammatori syndrom led patient death phase ii
trial
page
also decreas tumor-promot remodel blood vessel extracellular matrix within tumor
develop togeth astrazeneca
mrna encod human subunit deliv intratumor translat
mrna produc single-chain fusion protein secret produc cell
intratumor i/o asset incorpor featur reduc express hepatocyt
minim system toxic
recent effort space focus local deliveri minim toxic
deliveri approach includ viral vector unrat adenovir phase
studi combin ici
oncosec unrat deliv local via dna plasmid tavo inject intratumor deliv
cell via electropor current phase iib trial
tavo applic may limit tumor access electropor believ lnp-formul
may use viscer well access tumor see advantag
preclin data show synergi therapi
adapt moderna chardan
figur cytokin central regul anti-tumor immun
preclin data suggest turn cold tumor hot
use mous colon cancer line resist monotherapi partner astrazeneca
show moder tumor clearanc alon complet respons mice highest dose
shown left panel
combin treatment increas complet respons rate anim produc
complet respons lower dose vs microgram rna indic sensit
ind activ astrazeneca lead clinic develop
page
dose mous mrna day mous colon cancer cell resist checkpoint dose mous mrna day day moderna inc
astrazeneca plan phase studi expect multicent open-label design assess
alon combin checkpoint inhibitor
per moderna compani expect studi incorpor lower start dose mrna
intratumor i/o program could precaut light known toxic associ system
see reason measur yet know much leak tumor
effect level system exposur may human
background vaccin cytomegaloviru cmv infect
target congenit cytomegaloviru infect reduce/prev birth defect
adapt beltran cristea im expert proteom chardan
figur life cycl pathogenesi human cmv infect intric categor early- late-stag cycl
cmv infect world-wide adult popul remain latent lead life-long infect
cmv member -herp viru complex life cycl figur abil remain persist
absenc activ replic
although viru caus infect mostli asymptomat infect pregnant women lead
congenit infect result neurodevelopment abnorm babi
viru adopt latent form myeloid cell bone marrow lead life-long infect reactiv
page
cmv infect adult popul world-wide abl replic wide varieti cell
facilit effici transmiss spread human host well host
cmv present challeng immunocompromis subject includ organ transplant set
vaccin approv prevent congenit transmiss cmv
rate utero transmiss cmv higher primari infect occur pregnanc
bernstein et al indic babi born world congenit cmv infect repres
countri bernstein et al vaccin
primari cmv infect report occur pregnanc infant cmv infect
asymptomat birth infect develop symptom within year life rieder
cdc indic per babi born congenit cmv congenit cmv infect
get sick experi long-term health problem
risk utero transmiss primari infect due lack preexist immun
annual congenit cmv infect account hundr death thousand impair children
estim world-wide incid rate congenit cmv infect result birth cmv
infect us estim children born cmv asymptomat birth
absenc effect medicin cytomegaloviru import target mrna-bas vaccin develop
current diseas treatment strategi involv prevent especi absenc effect vaccin
multipl approach includ live attenu viru protein subunit plasmid dna viral vector
explor evalu vaccin candid cmv infect mcvoy clin infect
despit fact cmv genom long encod protein cmv vaccin develop
focus small fraction pathogen immunogen protein
viral glycoprotein gb instanc mediat fusion viru host cell explor
evalu vaccin cmv show partial efficaci bernstein et al vaccin
page
lnp-formul vaccin mrna encod cmv antigen
adapt corpor document chardan
figur deliv mrna encod viral antigen includ gb shown efficaci trial
pentamer complex well gb play role cmv transmiss primari infect
explor pentamer complex addit glycoprotein gb vaccin candid stem fact
protein mediat entri cmv variou cell type target neutral antibodi respons
cmv product
complex consist gh gl figur dolan et al virol
gb gh/gl complex enabl entri fibroblast cell entri endotheli epitheli cell
addit viral peptid includ requir interact gh/gl dimer
produc pentamer complex
neutral pentamer complex antibodi pregnanc associ reduc transmiss
cmv fetu
provid templat pentamer complex plu gb part cmv vaccin
pentam consist complex membran protein requir epitheli endotheli myeloid
cell infect viru produc provid mrna templat encod protein complex
complex also includ mrna encod cmv glycoprotein protein antigen shown efficaci
cmv figur bernstein et al vaccin
bulk natur immun respons individu lead cmv clearanc direct pentamer protein
preclin studi show induct neutral antibodi pentam gb
mrna-bas vaccin elicit potent durabl immun respons mice non-human primat
conduct studi investig whether antibodi gener follow vaccin lnp-
formul mrna-bas vaccin cmv john et al vaccin
page
mice non-human primat vaccin led durabl product neutral antibodi dose-
depend manner similar observ cmv seroposit individu
adapt corpor document chardan
figur design phase clinic trial vaccin develop cmv
conduct phase trial base preclin studi show robust efficaci platform
conduct random phase trial healthi adult assess safeti
reactogen immunogen escal dose level drug placebo
dose level phase studi enrol
addit dose level ad tbd plan test sentinel-expans phase
note although clinic trial link indic evalu compani halt
develop indic see page chose continu develop
page
new lnp manufactur process confer improv pharmaceut higher dose level test base safety/toler data inc
background vaccin candid chikungunya viru
use viral-lik particl vlp elicit immun respons chikungunya
chikungunya viru caus chikungunya fever transmit peopl mosquito
chikungunya diseas caus chikungunya viru contain envelop posit single-strand rna
genom kb size transmit human sever mosquito speci
chikungunya fever result high-tit viremia character fever rash sever joint pain lead
stooped-ov postur patient name chikungunya deriv
high-tit viremia viru transmit human-mosquito-human cycl
life-cycle alphaviru involv receptor-medi host cell entri follow viral-host cell membran fusion
lead releas viral genom initi process viral genom copi assembl new virion
adapt schwartz albert microbiol chardan
figur life cycl pathogenesi system dissemin chikungunya viru
page
healthi individu chikungunya viru effici clear within day infect action innat
immun system adapt immun respons kick figur
follow transmiss success replic site entri chikungunya viru dissemin target
cell organ circul system figur
increas world travel chikungunya viru becom global pathogen
cdc indic prior case relat chikungunya viru limit countri africa asia
europ indian pacif ocean http //www cdc gov/chikungunya/geo/index html
chikungunya viru becom global aid eas human travel one contin anoth
unit state decemb case report us state
multipl approach address chikungunya viru infect
approv vaccin therapeut prevent treat chikungunya viru infect
previou strategi address diseas involv develop vaccin candid includ inactiv
attenu live viru dna protein subunit well viral-lik particl among other tanab isb et al
develop prophylact vaccin modal antibodi
viru system secret therapeut modal
compani indic capabl produc deliv mrna templat encod entir
chikungunya viru capsid envelop protein lead product virus-lik particl vlp elicit
lnp-formul vaccin encod chikungunya viru structur polyprotein produc vlp
viral replic prior viral particl assembl produc virion viral structur protein produc
singl polyprotein process give capsid envelop well glycoprotein
vaccin strategi provid mrna templat encod full viral structur protein
assembl form virus-lik particl vlp abl elicit immun respons figur
adapt corpor document chardan
figur provid templat lead product viral-lik particl turn elicit immun respons
page
vlp assembl mrna encod structur protein immunogen
preclin studi show vlp strategi induc robust durabl neutral antibodi respons
result preclin studi vlp strategi mice non-human primat suggest approach
induc immun reaction dose-depend manner see page
mrna vaccin improv surviv mice challeng lethal dose chikungunya viru
day figur day figur vaccin
adapt corpor document chardan
figur mrna vaccin show durabl improv surviv dose-depend manner mice challeng lethal chikungunya viru
phase studi show dose-depend product neutral antibodi
evalu vaccin random placebo-control phase studi
result studi show dose-depend product persist neutral antibodi
chikungunya viru day post-dos titer notabl increas dose
percentag subject show serorespons depend dose highest dose reach
follow vaccin day figur
safeti report subject sever advers event grade elev serum ast grade
elev alt compani report resolv rapidli
trial on-going seek measur persist neutral antibodi well safeti year
second dose administ
adapt corpor document chardan
figur phase trial design result show neutral antibodi titer serorespons vaccin
page
background vaccin influenza
moderna mrna vaccin potenti swiftli address pandem situat
influenza caus influenza viru outbreak caus high morbid mortal rate
influenza infecti upper respiratori tract nose throat bronchi lung diseas caus influenza virus
character mani symptom includ high fever muscl pain headach sore throat
influenza introduc contact respiratori secret infect individu
viru rna genom variou viral factor includ hemagglutinin ha figur well host
condit influenc pathogen samji yale biol
type viru includ influenza
influenza virus caus season outbreak influenza caus pandem
pandem caus new strain influenza viru due chang viral genom result antigen
multipl influenza-rel pandem latest occur
adapt wahlgren jw infect epidemiol hutchinson ec trend microbiol chardan
figur replic cycl pathogenesi influenza viru host rang influenza viru wild bird center
genet drift influenza lead variabl circul antigen need new vaccin year-to-year
influenza virus broken multipl subtyp base hemagglutinin ha requir host
cell entri neuraminidas na protein requir host cell exit
cdc indic differ subtyp respect
page
although name influenza strain entail mani factor roughli nomenclatur take account
order discoveri human antibodi protein whenev new strain aris reflect
phylogenet divers viral membran protein figur
viral rna polymeras protein hijack host cell machineri replic viral genom process
rna polymeras prone mistak given lack proof-read machineri lead mutat rna
molecul assembl new virion repres high evolutionari rate pauli md et al elif
high mutat rate lead rapid evolut influenza viru emerg new viral strain pose
challeng result reduc vaccin efficaci emerg resist
effect vaccin depend antigen vitiat ha na glycoprotein influenza virus
complic fact influenza viru divers reservoir includ bird swine
pandem strain emerg figur
adapt liu et al virol chardan
figur error prone replic viral machineri lead phylogenet divers hemagglutinin neuraminidas
develop mrna therapeut candid could address pandem faster
epidem influenza estim affect popul associ larg econom burden
us estim influenza cost economi bn annual annual epidem estim
result mm sever ill case result approxim death
recent strain influenza viru exhibit featur could result epidem xiao
indic alreadi caus epidem mortal rate caus
epidem fatal
page
address pandem situat requir abil produc vaccin rapidli avoid induc featur
mani hamper potenc vaccin
current method use vaccin product lengthi could result featur hamper vaccin
potenc could present challeng pandem error refer sourc found figur
adapt hard ns vaccin chardan
figur approach influenza vaccin product nucleic-acid base approach includ mrna come variou advantag
demonstr efficaci clinic set
phase studi vaccin enrol subject
intramuscular intraderm differ dose group
compani report dose-depend seroconvers seroconvers dose figur
hemagglutinin inhibit persist month dose figur
safeti compani report dose well-toler sever solicit advers event erythema
headach report higher note compani proceed dose chose
discontinu intraderm dose due high rate advers event associ rout
page
current conduct phase studi vaccin strain
enrol particip dose level use vaccin schedul day day subject per dose day
trial compani report dose demonstr immunogen subject dose day day
subject dose respect show hemagglutinin inhibit
titer day figur
 dose hemagglutinin inhibitor titer persist observ month dose
particip remain seroposit titer month figur
adapt corpor document chardan
figur subject show ha inhibit titer persist titer month dose
adapt corpor document chardan
figur immunogen seen dose antibodi persist month dose
page
background vaccin zika viru
focus show insuffici immunogen
zika viru silent diseas agent recent caus outbreak disconcert patholog
zika viru contain positive-sens single-strand rna genom kb size transmit human
viru belong flaviviru genu includ vector-born pathogen virus yellow fever
dengu japanes enceph figur
viru also report transmit via non-vector rout includ blood transfus transplacent
sexual transmiss abl enter human cell receptor-medi endosom uptak figur
although zika viru infect previous associ mild symptom recent report lead
seriou complic includ guillain-barr syndrom adult neurolog defect microcephali
babi whose mother infect pregnanc meningoenceph fetal cerebr calcif central
nervou system alter myeliti koppolu shantha raju neurovirol
report indic spread viru result infect especi outbreak
america specif brazil well earlier massiv outbreak oceania bn peopl live area
prone diseas outbreak heinz fx stiasni microbiol mol biol revenue
effect treatment vaccin zika viru current strategi focus prevent
infect focu pregnant mother
adapt heinz fx stiasni microbiol mol biol chardan
figur flaviviru phylogenet tree show closest rel zika viru life cycl mechan fusion
anti-zika antibodi protect long-term report suggest may play role infect enhanc
neutral antibodi follow natur infect vaccin shown protect flavivirus
diseas howev preexist antibodi dengu exampl implic mediat infect
zika due cross reactiv durbin ap trend immunol
page
postul cross reactiv antibodi could also play role viral infect pregnanc
mediat transport viru across placent barrier
adapt corpor document chardan
figur mrna-bas vaccin zika viru encod protein intend produc virus-lik particl abl elicit immun respons
mrna-bas vaccin zika viru
encod structur protein pre-membran envelop protein prme zika viru
dose subject therapeut candid lead product virus-lik particl intend elicit
immun respons akin happen follow natur infect figur
next gener vaccin contain japanes enceph viru jev signal peptid distinct
formul compani proprietari lnp
preclin studi public design slightli mutat structur protein still elicit immun
respons time off-set cross-react antibodi postul lead transplacent infect
preclin studi vaccin day apart anim group non-human primat
challeng zika viru day dose dose investig figur
vaccin candid elicit equival immunogen show better protect base focu form
unit ffu dose non-human primat figur
adapt corpor document chardan
figur give better protect dose non-human primat
page
continu develop focus ind prepar instead
complet enrol phase trial design
vaccin schedul separ day evalu dose level vaccin
show suffici immunogen dose indic
focus effort develop potent current conduct ind-en
background respiratori syncyti viru rsv
merck unrat initi phase iia studi base phase trial result
adapt griffith et al clin microbiol bawag ss et al adv virol chardan
figur multipl mechan involv variou surfac protein enabl entri rsv host cell enabl life cycl
respiratori syncyti viru rsv infect common caus bronchiol pneumonia children
rsv common caus childhood acut respiratori infect main caus hospit
infanc import pathogen adult declin compromis immun system clinic featur
rang bronchiol wheez cold asthma exacerb insidi respiratori ill openshaw
et al ann immunol http //www cdc gov/rsv/index html
mm new rsv infect lower respiratori tract estim occur annual children year old
major death due rsv occur develop countri
although complet number avail current data indic annual basi rsv caus
hospit us emerg room visit children year age
specif treatment rsv new way address rsv could potenti transform global health
moderna rsv vaccin candid exploit viral protein involv entri host cell
page
viral entri host cell mediat interact viral surfac protein rsv-f rsv-g host cell
surfac receptor includ chemokin receptor toll-lik receptor heparan sulfat
proteoglycan hspg figur trigger cell fusion enabl rsv undergo life cycl figur
encod membran anchor rsv-f protein known target neutral
antibodi rsv design administ boost
rsv-f-base vaccin candid design pre-fus form compani indic superior
elicit immun reaction
current sponsor on-going phase studi plan partner merck unrat sponsor
safe well-toler shown immunogen phase studi
compani conduct phase trial studi fulli enrol healthi subject part part
age year part age year test dose level highest dose
dose lowest dose dose dose highest dose dose
base interim data day elicit humor immun respons subject group
dose-depend manner dose measur antibodi titer rsv-f protein absolut serum antibodi
titer rsv-f compet antibodi titer rsv-f figur
indic also observ increas cell respons rel baselin day subject
dose dose
safeti compani indic well-toler dose-limit toxic dose
dose administ older subject well toler compani indic
pattern clinic signific laboratori abnorm
observ sae subject deem unrel drug includ death pre-exist
base interim analysi merck compani partner initi plan phase iia trial
adapt corpor document chardan
figur led increas neutral anti-rsv antibodi titer rel placebo younger older healthi subject
page
background metapneumoviru mpv parainfluenza viru
potenti address pathogen caus respiratori tract infect
adapt schildgen et al clin microbiol moscona clin invest chardan
figur mpv entri host cell mediat viral fusion protein
metapneumoviru mpv caus respiratori tract infect re-infect common due weak immun
human mpv hmpv caus upper lower respiratori diseas children youth adult
immunocompromis individu lead rang mild life-threaten condit
hmpv major caus agent acut respiratori tract infect similar incid rate regardless
global preval hmpv infect among hospit patient estim lead
median cost median day length hospit patient popul mrquez-
children develop countri risk pneumonia compar develop countri
hmpv closely-rel rsv belong pneumovirida famili neg strand single-strand
rna genom kb encod viral protein includ nucleoprotein phosphoprotein matrix protein
hydrophob glycoprotein sh attach glycoprotein viral polymeras
infect caus hmpv rsv said clinic indistinguish re-infect due hpmv
common due weak natur immun
hmpv infect epitheli cell macrophag dendrit cell airway viral entri host cell
mediat viral protein figur schildgen et al clin microbiol
vaccin approv prevent hmpv infect
parainfluenza viru lead caus respiratori tract infect infant children
page
parainfluenza viru hpiv belong paramyxovirida famili single-strand rna viru
genom kb encod structur protein includ larg nucleocapsid phosphoprotein
nucleocapsid hemagglutinin-neuraminidas hn fusion membran protein
hpiv divid major subtyp respiroviru rubulaviru
base genom
virul hpiv associ signific morbid mortal
common rsv caus acut respiratori tract infect children adult weaken immun system
associ bronchiol bronchiti pneumonia
hpiv infect typic result mild diseas symptom may also associ worsen chronic airway
diseas includ asthma chronic obstruct pulmonari diseas copd chronic rhinosinus
estim mm lower respiratori tract ill occur us annual hpiv account acut
respiratori tract infect hospit children year old
serolog survey indic children infect age year number rise
age year paweczyk kowalski curr allergi asthma rep
entri cell begin fusion viral membran host cell membran mediat
host defens mechan involv immun viral hn protein
vaccin approv
develop combin vaccin hmpv
develop vaccin combin mrna encod sequenc viral membran fusion protein
hmpiv figur
evalu preclin studi involv multi-speci anim model hmpv
shown exampl mice vaccin candid abl elicit immun respons variou
dose level lead gener antibodi titer protect pathogen
compani current conduct phase studi fulli enrol subject
trial test dose level vaccin candid compar placebo
per compani interim analysi safeti immunogen find indic vaccin mrna-
boost serum neutral titer hpmv dose level test lead titer
baselin month vaccin respect
vaccin increas antibodi titer pre-expos popul healthi adult
safeti exhibit favor profil gener well toler seriou advers event
base data phase ib studi evalu safeti immunogen toddler
current design
page
adapt corpor document chardan
figur combo vaccin mrna encod fusion protein mpv
adapt corpor document chardan
figur preclin studi gener neutral antibodi hmpv phase clinic trial design
page
background ischem heart failur
produc vascular endotheli growth factor vegf-a stimul angiogenesi
adapt http //www nhlbi nih gov/health-topics/coronary-heart-diseas taimeh et al cardiol chardan
figur reduc oxygen suppli heart muscl lead coronari heart diseas vegf-a play role growth new blood vessel
coronari heart diseas result restrict reduc oxygen suppli heart muscle/tissu
indic mm peopl die year cardiovascular diseas due heart attack
stroke occur low- middle-incom countri
unit state peopl die annual heart diseas repres death
cardiovascular diseas result disord heart blood vessel ultim result condit
includ coronari arteri diseas heart failur cardiac arrest sudden cardiac death
coronari arteri diseas danger heart diseas oxygen suppli heart muscl restrict reduc
due narrow coronari heart arteri lead heart failur due mismatch demand suppli
oxygen taimeh loughran birk bolli cardiol
narrow heart vessel result accumul atherosclerot plaqu consist lipid calcium deposit
cellular debri molecular cellular caus mechan poorli understood figur
adult human lack abil regener heart tissu follow injuri molecular mechan underli
restor damag tissu differ speci continu unfold uygur rt dev cell
vascular endotheli growth factor vegf-a play role growth new blood vessel
reduc level vascular endotheli growth factor vegf-a whose biolog function mediat vascular
endotheli growth factor receptor transmembran glycoprotein observ
model advanc heart failur taimeh loughran birk bolli cardiol
vegf play signific role growth new blood vessel involv sever process includ
angiogenesi process format new blood vessel arteriogenesi process blood vessel
page
enlarg vasculogenesi format primit vascular network absenc exist
vegf-a subtyp vegf divid isoform base differenti splice vegf-a mrna secret
variou cell type includ endotheli cell multipot stem cell matur cardiomyocyt
vegf-a signal promot prolifer differenti cell lead angiogenesi format new
adapt corpor document chardan
figur phase studi led dose-depend vegf-a protein product increas blood flow
encod product vascular endotheli growth factor vegf-a
collabor astrazeneca unrat develop local product vascular
endotheli growth factor vegf-a ischem heart failur
therapeut candid intend promot re-vascular heart tissu stimul growth blood
vessel increas blood suppli thu oxygen damag tissu
salin formul deliv local damag heart tissu
astrazeneca conduct phase ia/ib studi enrol men type diabet mellitu
involv intraderm inject drug candid
phase ia/ib studi divid part singl ascending-dos subject drug placebo dose
cohort part pharmacodynam subject dose placebo
per moderna drug candid met primari object safeti toler well secondari
object dose-depend protein product chang blood flow figur gan l-m et al
program move phase iia studi expect enrol patient provid
initi safeti toler data coronari arteri bypass patient
page
system secret therapeut target chikungunya viru heart diseas fabri diseas
system secret therapeut design increas concentr desir protein
system secret therapeut modal aim increas level desir protein across multipl
diseas area current address variou approach includ enzym replac therapi
antibodi
compani program modal includ
produc antibodi protect anim model chikungunya preclin studi
develop allianc darpa encod antibodi chikungunya viru see
iv administr led product antibodi titer protect chikungunya anim model
challeng viru
conduct random placebo-control phase studi healthi
deliv intraven infus studi evalu pharmacokinet dose
pharmacodynam express antibodi level whether level suffici neutral viru infect
assay
adapt corpor document chardan
figur preclin nhp data left phase trial design evalu rang dose
iv dose lead prolong product relaxin protein rodent non-human primat
develop collabor astrazeneca design secret engin long-act
relaxin protein heart failur see page
relaxin endogen hormon shown benefit cardiac function devarakonda salloum
page
indic lead protein express day comparison standard recombin relaxin
compani indic observ earlier studi exhibit half-lif minut
singl dose reduc globotriaosylsphingosin marker fabri diseas
design secret alpha galactosidas -gal enzym defici fabri diseas see page
administr drug mous model diseas led reduct diseas marker
importantli anti-drug antibodi observ
system intracellular therapeut target mma pa pku
system intracellular therapeut enabl express intracellular protein
moderna system intracellular therapeut design increas level intracellular protein
enzym mutat rare genet diseas
program modal includ methylmalon acidemia mma propion acidemia
pa phenylketonuria pku
increas surviv anim model methylmalon acidemia mma
encod product intracellular protein methylmalonyl-coenzym mutas mut see s-
administr human mut mrna anim model diseas led reduc toxic diseas metabolit
increas surviv treat anim compar control
receiv fda pediatr diseas design rpdd track design ftd orphan
drug design odd well odd european medicin agenc ema
current conduct natur histori studi identifi correl clinic
biomark endpoint submit ind phase i/ii studi
ind phase i/ii trial mma current open though studi yet recruit patient
adapt corpor document chardan
figur design plan phase i/ii studi methylmalon acidemia
design produc complex propionyl-coa carboxylas enzym propion acidemia pa
page
phase i/ii elig patient age isol mma due mut deficiencymetr safeti pk pd plasma mma level initi dose level enrol adolesc age includ children safeti toler determin moderna inc
contain mrna encod product propionyl-coa carboxylas pcc subunit
iv administr pa mice led product pcc decreas level diseas marker
 plasma ammonia well improv diseas symptom
receiv rpdd odd fda
also conduct natur histori studi identifi correl clinic
biomark endpoint also plan phase i/ii dose-escal studi
design produc phenylalanin hydroxylas pah enzym defici pku patient
phenylketonuria pku result defici pah enzym lead aberr metabol phenylalanin see
pku control maintain restrict diet control phenylalanin intak
contain mrna encod product pah
repeat dose iv pku mous model led reduct phenylalanin level diseas
current conduct ind-en studi program
page
figur modernaincom statement million except ep
page
million except product collabor revenu includ grant gener oper incom incom incom incom incom incom basic dilut ep ep cash shareholdersdividend size incom product collabor revenu includ grant gener oper incom incom incom incom incom incom inc
sale key product
figur modernaproduct revenu million
page
rsv-f mrna im rsv vaccin pi pentamer mrna plu gb im cmv pi mrna im pc vzv antigen mrna im vzv vaccin pi ha mrna im pi ha mrna im ind prm-e mrna im zika pi mrna im chikungunya pipelin support termin pcv neoantigen mrna im pcv sale pi kra neoantigen mrna im nsclc pc share pipelin support termin pi mrna tu solid tumor pi mrna tu solid tumor ind mrna tu solid tumor us sale ind mrna tu solid tumor ex-u pipelin support termin regen vegf-a mrna im myocardi ischemia secret pi igg mrna iv pc relaxin mrna iv heart failur sale pc -gal mrna iv fabri pipelin support termin intracellular ind mut mrna iv pc pcca pccb mrna iv pc pah mrna iv pipelin support termin product sale yoy product yoy product yoy inc
figur modernadiscount cash flow dcf analysi million
page
million except per share net depreci capit increas work defer non-cash free cash first year cash unlev free cash period discount period discount year mid-year factor free cash valu unlev free cash pv forecast unlev free cash valu perpetu growth valu termin termin ebitda xenterpris valu per dilut assumptionswacc calculationsbal sheetdcf valu alloc product cash fiscal year end fiscal year end project discount regen project discount per secret dilut share price intracellular perpetu growth market cap cash per valu per march share exercis share restrict common share restrict common stock model dilut million inc
